Athenex (NASDAQ:ATNX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Friday.
A number of other brokerages have also recently issued reports on ATNX. BidaskClub cut Athenex from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 19th. Zacks Investment Research cut Athenex from a “buy” rating to a “hold” rating in a report on Friday, March 30th. Finally, Needham & Company LLC started coverage on Athenex in a report on Tuesday, March 6th. They issued a “buy” rating and a $30.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Athenex presently has a consensus rating of “Buy” and a consensus price target of $26.71.
Athenex stock opened at $17.91 on Friday. The company has a market capitalization of $1.06 billion and a price-to-earnings ratio of -7.72. Athenex has a 12 month low of $12.30 and a 12 month high of $20.79.
In related news, Director Song-Yi Zhang sold 29,244 shares of the firm’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $16.93, for a total transaction of $495,100.92. Following the completion of the sale, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $67,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Rudolf Kwan purchased 2,000 shares of the company’s stock in a transaction that occurred on Monday, March 26th. The shares were acquired at an average cost of $14.65 per share, with a total value of $29,300.00. Following the completion of the acquisition, the executive vice president now directly owns 82,224 shares in the company, valued at $1,204,581.60. The disclosure for this purchase can be found here. Over the last three months, insiders bought 29,500 shares of company stock valued at $433,850 and sold 301,392 shares valued at $5,041,671. Corporate insiders own 29.50% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Virtus Fund Advisers LLC acquired a new stake in Athenex during the 4th quarter valued at $333,000. BlackRock Inc. increased its holdings in Athenex by 253.0% during the 4th quarter. BlackRock Inc. now owns 1,086,985 shares of the company’s stock valued at $17,282,000 after purchasing an additional 779,092 shares in the last quarter. Private Advisor Group LLC acquired a new stake in Athenex during the 4th quarter valued at $161,000. Prince Street Capital Management LLC acquired a new stake in Athenex during the 4th quarter valued at $2,798,000. Finally, Goldman Sachs Group Inc. increased its holdings in Athenex by 176.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 87,427 shares of the company’s stock valued at $1,390,000 after purchasing an additional 55,795 shares in the last quarter. 16.63% of the stock is owned by hedge funds and other institutional investors.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.